Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

Drug maker Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies , a biopharmaceutical company, Bloomberg ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

Pharmaceutical giant Johnson & Johnson (J&J) (NYSE:JNJ) has announced plans to acquire Intra-Cellular Therapies (NASDAQ:ITCI) ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Study from neutral host providers discovers how Wi-Fi and cellular connectivity have overtaken traditional priorities like price and amenities as top considerations for businesses choosing commercial ...

The Intra-Cellular deal will give J&J access to the company's drug Calypta, which is used in the US to treat schizophrenia ...

TickTalk is the first kids' US-based smartwatch company to use AI technology to correct and update locations resulting in unmatched reliability. This new feature can be found on the Parental Control ...